Lou Gehrig's disease

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...

South Korean genome editing developer ToolGen Inc. announced on Monday that its application for orphan drug designation (ODD) of the gene correction...

South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain ima...

South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical Schoo...

South Korea's digital healthcare startup ichrogene, with investment from Naver D2 Startup Factory (D2SF), entered into Thai market. Naver Corp....

South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...

South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...

South Korean vaccine developer Quratis Inc. on Wednesday announced its signing of a term sheet on the direction and major transaction terms of coope...

South Korean medical diagnostic company NGeneBio Co. announced on Thursday that it has completed the US patent application for its technology relate...

South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partn...

South Korea's Yungjin Pharm has secured Fast Track designation from the US Food and Drug Administration (FDA) for its new drug candidate KL1333, des...